Hemoglobin News and Research

RSS

Novartis receives FDA approval for Exjade to treat chronic iron overload in NTDT patients

The U.S. Food and Drug Administration today expanded the approved use of Exjade (deferasirox) to treat patients ages 10 years and older who have chronic iron overload resulting from a genetic blood disorder called non-transfusion-dependent thalassemia (NTDT).

23 Jan 2013

Biophysical Society Annual Meeting to highlight innovations in medicine, physics, and more

Honeybee silk-inspired materials; a deconstruction of the Ebola virus; how microbes evolve resistance to antibiotics; and a possible connection between Alzheimer's disease and type II diabetes are just some of the intriguing topics that will be presented at the 57th Annual Meeting of the Biophysical Society (BPS).

22 Jan 2013

Intermountain Risk Score tool can predict mortality among trauma patients

A simple, inexpensive blood test performed on trauma patients upon admission can help doctors easily identify patients at greatest risk of death, according to a new study by researchers at Intermountain Medical Center in Salt Lake City.

18 Jan 2013

Top-line results from Amgen’s Aranesp Phase 3 trial on heart failure and anemia

Amgen today announced top-line results of the Phase 3 Aranesp (darbepoetin alfa) RED-HF (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial.

17 Jan 2013

Raising transfusion threshold improves acute upper GI bleeding outcomes

Outcomes among patients with acute upper gastrointestinal bleeding can be improved by employing a restrictive transfusion strategy that raises the threshold for the transfusion of red cells, the results of a Spanish study indicate.

4 Jan 2013

No significant difference in patient outcomes with RBC transfusions using lower threshold levels

The level at which red blood cells are transfused, a common treatment in clinical practice, is often deliberated among physicians. Guidelines for blood transfusion levels were only recently issued in March 2012 diminishing some of the debate. Today, in a new section called JAMA Clinical Evidence Synopsis, the Journal of the American Medical Association (JAMA), published a summary of the systematic review of the 19 clinical trials that compare higher versus lower hemoglobin thresholds in red blood cell transfusion.

3 Jan 2013

Concern over transfusions in myocardial infarction patients

A meta-analysis highlights the consistent observational finding that patients with myocardial infarction who receive blood transfusions are at high risk for dying.

28 Dec 2012

Protein in human blood platelets points to a new weapon against malaria

One of the world's most devastating diseases is malaria, responsible for at least a million deaths annually, despite global efforts to combat it. Researchers from the Perelman School of Medicine at the University of Pennsylvania, working with collaborators from Drexel University, The Children's Hospital of Philadelphia, and Johns Hopkins University, have identified a protein in human blood platelets that points to a powerful new weapon against the disease. Their work was published in this months' issue of Cell Host and Microbe.

28 Dec 2012

Blood transfusion for patients with myocardial infarction associated with increased all-cause mortality

A meta-analysis of 10 studies suggests that receipt of a blood transfusion among patients with myocardial infarction (heart attack) was associated with increased all-cause mortality compared with not receiving a blood transfusion during heart attack, according to a report published Online First by Archives of Internal Medicine, a JAMA Network publication.

25 Dec 2012

AMAG seeks FDA sNDA approval for Feraheme Injection

AMAG Pharmaceuticals, Inc. today announced that it has submitted a supplemental new drug application (sNDA) to the United States Food and Drug Administration (FDA) for Feraheme (ferumoxytol) Injection for Intravenous (IV) use.

25 Dec 2012

Updated U.S. prescribing information for Boehringer Ingelheim’s Pradaxa

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. prescribing information for Pradaxa (dabigatran etexilate mesylate) capsules was updated to include a contraindication related to use in patients with mechanical prosthetic heart valve replacement.

21 Dec 2012

Astellas, FibroGen commence FG-4592/ASP1517 Phase 3 clinical program in CKD anemia

FibroGen, Inc., and Astellas Pharma Inc., announced today the initiation of the first clinical study in the Phase 3 clinical development program of FG-4592/ASP1517, an orally administered small molecule, for treatment of anemia associated with chronic kidney disease ("CKD") in patients not on dialysis and on dialysis, to support approval in the U.S. and Europe.

12 Dec 2012

AMAG presents new data from two ferumoxytol phase III trials on IDA at ASH annual meeting

AMAG Pharmaceuticals, Inc. today announced that new data from two pivotal phase III clinical trials were presented at the American Society of Hematology's (ASH) annual meeting in Atlanta, Georgia.

11 Dec 2012

Acetylon announces results from selective HDAC 1/2 inhibitor preclinical study on SCD and bT

Acetylon Pharmaceuticals Inc., a leader in targeted epigenetic drug discovery and development for enhanced therapeutic outcomes, today announced results from a preclinical study of a selective histone deacetylase (HDAC) 1/2 inhibitor for the treatment of sickle cell disease (SCD) and beta-thalassemia (bT) at the 54th Annual Meeting of the American Society of Hematology (ASH), taking place in Atlanta, Georgia.

11 Dec 2012

New technology allows noninvasive SpHb assessments for children undergoing brain surgery

For children undergoing brain surgery, a new technology allows noninvasive, continuous monitoring of blood hemoglobin levels, according to a study in the December issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

6 Dec 2012

NOXXON commences NOX-H94 Phase IIa trial to treat anemia of chronic disease

NOXXON Pharma today announced the treatment of the first patients in a Phase IIa clinical trial of its anti-hepcidin Spiegelmer NOX-H94 to treat anemia associated with chronic disease.

5 Dec 2012

Diabetes education critical for uncontrolled high blood sugar people with cancer

When people with Type 2 diabetes are diagnosed with cancer -- a disease for which they are at higher risk -- they ignore their diabetes care to focus on cancer treatment, according to new Northwestern Medicine- research. But uncontrolled high blood sugar is more likely to kill them and impairs their immune system's ability to fight cancer.

30 Nov 2012

14 new human monoclonal antibodies introduced by Beckman Coulter Life Sciences

Beckman Coulter Life Sciences is expanding their flow cytometry portfolio with the addition of 14 new human monoclonal antibodies from Trillium Diagnostics LLC.

From Beckman Coulter Life Sciences - Flow Cytometry 30 Nov 2012

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted to hematology and breast cancer, demonstrating continued innovation in research and development efforts to advance the care of patients with cancer and rare diseases.